Heyuan Biotechnology

Heytian Bio offers a range of viral vector products, including adeno-associated virus (AAV), lentivirus, adenovirus, and retrovirus, for gene delivery solutions.

Heytian Bio, Kobe International Medical Exchange Foundation, and Yuuai Co. signed a memorandum of cooperation in Shanghai to explore advanced regenerative medicine in R&D, clinical collaboration, and international exchange.

Heytian Bio recruits recent graduates for roles in viral vector R&D, biotechnology, and quality management in gene therapy.

Heytian Bio lists open positions in viral vector R&D, quality management, and production technology for gene therapy professionals.

Heytian Bio highlights industry awards, technical prizes, and certifications in gene therapy and viral vector fields.

Heytian Bio reviews its development milestones from founding to listing (stock code: 688238) in viral vector and gene therapy CDMO.

Heytian Bio provides contact details for inquiries about viral vector R&D, gene therapy CDMO services, and technical support.

Heytian Bio specializes in viral vector R&D and gene therapy CDMO services, providing AAV, lentivirus, and adenovirus packaging for drug development.

OBiO Technology partners with Renyuan Biotechnology to advance **EPC (endothelial progenitor cell) therapy** through preclinical CMC research and IND filing. The collaboration covers the full development pipeline, aiming to standardize and accelerate the therapy’s transition toward clinical trials. Both companies will work jointly on regulatory and manufacturing readiness for the cell-based treatment.

Oct 2026Insight, China's Pharmaceutical IndustryNews article

China’s OBiO Technology teams with Hanxin Biotechnology to develop lipid nanoparticle (LNP) delivery systems for mRNA and nucleic acid therapies. The partnership targets clinical applications in vaccines and cancer treatments, leveraging both firms’ expertise in gene therapy. Financial terms of the collaboration remain undisclosed.

Nov 2024Insight, China's Pharmaceutical IndustryNews article

OBiO Technology provides preclinical research services to Shenzhen Innovation Immunotechnology for its TCR-T cell therapy candidate, **SIIT-T002**. The partnership supports Shenzhen Innovation’s efforts to streamline the **Investigational New Drug (IND) filing** process for its pipeline. OBiO, a China-based **gene therapy-focused CRO**, specializes in accelerating drug development through contract research.

Jun 2024Insight, China's Pharmaceutical IndustryNews article

OBiO Technology secures FDA acceptance of its GMP plasmid DNA drug master file (DMF), numbered **037766**. The approval streamlines future investigational new drug (IND) filings for lentiviral vector-based therapies. OBiO operates as a contract research and manufacturing organization specializing in gene and cell therapy development.

Jan 2023PR NewswireNews article